Bluher AE, et al. - Among 31 children (mean age was 6.8 years) with mild obstructive sleep apnea treated with montelukast and fluticasone, researchers assessed the quality of life. For this investigation, children between the ages of 3 and 16 with mild sleep apnea (apnea-hypopnea index > 1 and ≤ 5) were prospectively recruited and treated with 4 months of montelukast and fluticasone. Investigators found that children treated with fluticasone and montelukast with mild obstructive sleep apnea experience significant improvements in quality of life. Demographic factors like obesity and apnea-hypopnea index did not predict which children would react to anti-inflammatory drugs.